At what enterprise value was GERMITEC acquired in 2025?

You can find the full valuation details of GERMITEC on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of GERMITEC when it was acquired by EURAZEO / TURENNE CAPITAL / KURMA PARTNERS?

The exact EV/EBITDA multiple for GERMITEC is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

What was the revenue of GERMITEC at the time of the deal?

The revenue of GERMITEC at the time of the deal is estimated to be in the range of 5M - 25M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the GERMITEC acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the GERMITEC deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.cfnews.net/Les-alertes-de-CFNEWS/Germitec-irradie-aux-Etats-Unis-518292

← DATABASE

Home Database Healthcare & PharmaGERMITEC

02/2025

GERMITEC acquired by EURAZEO, TURENNE CAPITAL & KURMA PARTNERS

FRANCE Life Sciences / Medical Devices REV 5M - 25M EUR

Context

Germitec raised EUR29 million in a Series B round led by Eurazeo to accelerate its commercial expansion in the United States. The company recently achieved a major regulatory milestone by obtaining FDA "De Novo" clearance in September 2024. The funds will be used to scale the US team and compete against chemical-based incumbents. Historical investors, including Kurma Partners (a Eurazeo subsidiary), Financiere Arbevel, and Turenne Capital, participated in the round. The financial investors now hold the majority of the capital.

GERMITEC, which reported an EBITDA margin of in 2024, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Germitec is a French MedTech company revolutionizing infection control in hospitals with its proprietary High-Level Disinfection (HLD) technology for ultrasound probes. Unlike traditional chemical methods (soaking or wipes) used by competitors like Nanosonics, Germitec's flagship system, Chronos®, utilizes UV-C photon technology to disinfect probes in just 90 seconds. This automated, chemical-free solution significantly improves clinical workflow efficiency while eliminating toxic risks for medical staff and patients.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
03/2025	ZYDUS	AMPLITUDE SURGICAL	FRANCE	Implants & Prosthetics
03/2025	NUTRISENS	PRODIET	BRAZIL	Nutrition & Dietary Supplements
02/2025	NOVONESIS	FEED ENZYME ALLIANCE	DENMARK	Animal Health
01/2025	QUADRIVIO GROUP	MIR - MEDICAL INTERNATIONAL RESEARCH	ITALY	Diagnostic Equipment
12/2024	NEXTSTAGE / IK PARTNERS	EUROBIO SCIENTIFIC	FRANCE	Diagnostic Equipment
12/2024	GOLDMAN SACHS	Synthon International	NETHERLANDS	Generics / Labs
12/2024	UI INVESTISSEMENT	DIDACTIC	FRANCE	Medical Consumables
11/2024	NAXICAP PARTNERS	GLOBAL D	FRANCE	Implants & Prosthetics
10/2024	CLAYTON, DUBILIER & RICE (CD&R)	OPELLA	FRANCE	Generics / Labs
10/2024	BANSK GROUP	PETIQ	UNITED STATES	Animal Health

REFERENCES

Revenue range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of GERMITEC by EURAZEO / TURENNE CAPITAL / KURMA PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: eurazeo / kurma partners / turenne capital